Fibrous dysplasia as a possible false-positive finding in 68Ga-labeled prostate-specific membrane antigen positron emission tomography/computed tomography study in the follow-up of prostate cancer

André Marcondes Braga Ribeiro; Eduardo Nóbrega Pereira Lima; Maurìcio Murce Rocha

doi:10.4103/wjnm.WJNM_111_18

World Journal of Nuclear Medicine, Table of Contents

CC BY-NC-ND 4.0 · World J Nucl Med 2019; 18(04): 409-412
DOI: 10.4103/wjnm.WJNM_111_18

Case Report

Fibrous dysplasia as a possible false-positive finding in ⁶⁸Ga-labeled prostate-specific membrane antigen positron emission tomography/computed tomography study in the follow-up of prostate cancer

André Marcondes Braga Ribeiro

Department of Nuclear Medicine, A. C. Camargo Cancer Center, São Paulo, Brazil

,

Eduardo Nóbrega Pereira Lima

Department of Nuclear Medicine, A. C. Camargo Cancer Center, São Paulo, Brazil

,

Maurìcio Murce Rocha

¹Department of Urology, A. C. Camargo Cancer Center, São Paulo, Brazil

› Author Affiliations

Abstract

Positron emission tomography/computed tomography (PET/CT) using ⁶⁸Ga-labeled prostate-specific membrane antigen (⁶⁸Ga-PSMA) has become an important tool in restaging patients with prostate cancer (PCa). Despite its high sensitivity and specificity, this method may produce false-positive findings, as indicated by previous studies. This case report aims to warn nuclear medicine physicians, oncologists, and urologists about the possibility of false-positive findings using this imaging modality, especially when the detected site is unusual for bone metastasis. A 68-year-old man with PCa underwent restaging tests after presenting with increased prostate-specific antigen.⁶⁸Ga-PSMA PET/CT imaging revealed abnormal uptake in the left humeral head, which anatomically corresponded to the intramedullary and cortical sclerotic area. A biopsy was performed, and the pathology showed a lesion consisting of hard bone tissue with a small focal spot of fibrous dysplasia. Diagnostic issues related to ⁶⁸Ga-PSMA PET/CT imaging should be disseminated to help physicians make appropriate treatment choices for each patient.

Keywords

⁶⁸Ga-labeled prostate-specific membrane antigen - bone metastasis - false-positive result - fibrous dysplasia - prostate cancer

Full Text

References

References
1 Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C. Global burden of urologic cancers, 1990-2013. Eur Urol 2017;71:437-46.
2 Dodds PR, Caride VJ, Lytton B. The role of vertebral veins in the dissemination of prostatic carcinoma. J Urol 1981;126:753-5.
3 Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive ⁶⁸Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis. Eur Urol 2016;70:926-37.
4 Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging 2017;44:2117-36.
5 De Coster L, Sciot R, Everaerts W, Gheysens O, Verscuren R, Deroose CM, et al. Fibrous dysplasia mimicking bone metastasis on ⁶⁸GA-PSMA PET/MRI. Eur J Nucl Med Mol Imaging 2017;44:1607-8.
6 Rowe SP, Macura KJ, Ciarallo A, Mena E, Blackford A, Nadal R, et al. Comparison of prostate-specific membrane antigen-based 18F-DCFBC PET/CT to conventional imaging modalities for detection of hormone-naïve and castration-resistant metastatic prostate cancer. J Nucl Med 2016;57:46-53.
7 Fitzpatrick KA, Taljanovic MS, Speer DP, Graham AR, Jacobson JA, Barnes GR, et al. Imaging findings of fibrous dysplasia with histopathologic and intraoperative correlation. AJR Am J Roentgenol 2004;182:1389-98.
8 Gorin MA, Rowe SP, Denmeade SR. Clinical applications of molecular imaging in the management of prostate cancer. PET Clin 2017;12:185-92.
9 Fendler W, Calais J, Gartmann J, Nickols NG, Reiter RE, Rettig M, et al. Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial. J Clin Oncol 2018;36:5001.
10 Rai BP, Baum RP, Patel A, Hughes R, Alonzi R, Lane T, et al. The role PET with (68) gallium (Ga)-labelled prostate-specific membrane antigen (PSMA) in the management of patient with organ confined and locally advanced prostate cancer prior to radical treatment and after radical prostatectomy. Urology 2016;95:11-5.